We observed drug-related adverse reactions and graded according to CTCAE (17) in both groups, simultaneously analyzing changes in tumor CD8+ T cells, TAMs, CAFs counts, immunohistochemistry score changes before and after treatment, and their correlation with treatment efficacy. The gene discussed is CD8A; the disease is neoplasm.